Although SGLT2 inhibitors were reported to decrease the risk of atrial fibrillation, clinical practice data were not available to demonstrate and confirm the antiarrhythmic effect of SGLT2 inhibitor therapy [15]. The gene discussed is SLC5A2; the disease is atrial fibrillation.